Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Ludwig, 1978, Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis), Virchows Arch A Pathol Anat Histol, 379, 103, 10.1007/BF00432479 Pells, 2013, The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort, J Hepatol, 59, 67, 10.1016/j.jhep.2013.02.019 Poupon, 1991, A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis, N Engl J Med, 324, 1548, 10.1056/NEJM199105303242204 Angulo, 1999, Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis, Hepatology, 29, 644, 10.1002/hep.510290301 Poupon, 1994, Ursodiol for the long-term treatment of primary biliary cirrhosis, N Engl J Med, 330, 1342, 10.1056/NEJM199405123301903 Corpechot, 2000, The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis, Hepatology, 32, 1196, 10.1053/jhep.2000.20240 Carbone, 2016, The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis, Hepatology, 63, 930, 10.1002/hep.28017 2017, EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis, J Hepatol, 145, 167 Carbone, 2013, Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid, Gastroenterology, 144, 560, 10.1053/j.gastro.2012.12.005 Liu, 2010, Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis, Nat Genet, 42, 658, 10.1038/ng.627 Lammers, 2014, Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study, Gastroenterology, 147, 1338, 10.1053/j.gastro.2014.08.029 Huang, 2013, Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome, Liver Int, 33, 1249, 10.1111/liv.12184 Carpino, 2018, Hepatic stem/progenitor cell activation differs between primary sclerosing and primary biliary cholangitis, Am J Pathol, 188, 627, 10.1016/j.ajpath.2017.11.010 Semeraro, 2012, Multipotent stem/progenitor cells in the human foetal biliary tree, J Hepatol, 57, 987, 10.1016/j.jhep.2012.07.013 Cardinale, 2012, The biliary tree—a reservoir of multipotent stem cells, Nat Rev Gastroenterol Hepatol, 9, 231, 10.1038/nrgastro.2012.23 Nattino, 2014, A new calibration test and a reappraisal of the calibration belt for the assessment of prediction models based on dichotomous outcomes, Stat Med, 33, 2390, 10.1002/sim.6100 Alvaro, 2004, Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis, J Hepatol, 41, 905, 10.1016/j.jhep.2004.08.022 McKinney, 2015, T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection, Nature, 523, 612, 10.1038/nature14468 Lanzoni, 2016, The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: a new reference frame for disease and regeneration, Hepatology, 64, 277, 10.1002/hep.28326 Nakanuma, 2010, Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement, Pathol Int, 60, 167, 10.1111/j.1440-1827.2009.02500.x Corpechot, 2018, A placebo-controlled trial of bezafibrate in primary biliary cholangitis, NEJM, 378, 2171, 10.1056/NEJMoa1714519 Jones, 2017, Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study, Lancet Gastroenterol Hepatol, 2, 716, 10.1016/S2468-1253(17)30246-7